New Brunswick-based Johnson & Johnson said Wednesday it is mobilizing resources at its Janssen Pharmaceutical Cos. to launch a multi-pronged response to the novel coronavirus (also known as 2019-nCoV or Wuhan coronavirus) outbreak. As part of this work, the company initiated efforts to develop a vaccine candidate against 2019-nCoV and broadly collaborate with others to screen a library of antiviral therapies. Please read more here.